Workflow
九安医疗(002432) - 2021 Q1 - 季度财报
ANDON HEALTHANDON HEALTH(SZ:002432)2021-04-27 16:00

Financial Performance - The company's operating revenue for Q1 2021 was CNY 322,180,761.49, representing a 6.93% increase compared to CNY 301,292,856.79 in the same period last year[3]. - Net profit attributable to shareholders was CNY 38,035,813.70, a decrease of 17.24% from CNY 45,956,809.95 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 1,895,575.99, down 95.90% from CNY 46,213,011.12 in the previous year[3]. - Basic and diluted earnings per share were both CNY 0.0849, down 20.06% from CNY 0.1062 year-on-year[3]. - The total operating revenue for the first quarter was CNY 157,579,002.81, a decrease of 16.46% compared to CNY 188,583,957.81 in the previous year[32]. - The net profit attributable to shareholders of the parent company was CNY 38,035,813.70, down 17.2% from CNY 45,956,809.95 in the same period last year[29]. - The company reported a net profit of CNY 22,073,582.57, a decrease of 55.5% compared to CNY 49,571,188.27 in the previous year[29]. - The total comprehensive income for the quarter was CNY 25,437,912.70, a decrease of 53.8% from CNY 54,979,925.38 in the previous year[31]. Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 37,538,104.40, a decline of 165.24% compared to CNY 57,534,224.65 in the same period last year[3]. - Cash inflow from operating activities totaled CNY 313,896,701.96, down from CNY 374,666,976.95 in the previous period, reflecting a decline of approximately 16.2%[36]. - Cash inflow from investment activities was CNY 20,232,240.82, significantly lower than CNY 383,197,757.59 in the previous period, marking a decrease of about 94.7%[36]. - Cash outflow from investment activities reached CNY 107,500,479.39, compared to CNY 314,902,077.10 in the previous period, indicating a reduction of approximately 65.8%[36]. - Cash inflow from financing activities was CNY 315,999,996.90, a substantial increase from CNY 68,867,857.98 in the previous period, representing an increase of about 359.5%[37]. - The ending balance of cash and cash equivalents was CNY 679,796,857.18, up from CNY 268,127,255.60 in the previous period, reflecting an increase of approximately 153.5%[37]. - The company reported a cash balance of CNY 913,712,950.35 as of January 1, 2021, indicating strong liquidity[41]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,719,507,624.34, an increase of 10.61% from CNY 2,458,560,510.72 at the end of the previous year[3]. - The total liabilities decreased to CNY 560,347,270.01 from CNY 636,093,577.60, indicating a reduction of approximately 11.9%[24]. - The total current assets increased to RMB 1,949,429,751.07 from RMB 1,675,278,853.67[21]. - The company's total current liabilities amounted to CNY 413,422,748.88, down from CNY 499,162,488.67, reflecting a decrease of approximately 17.2%[24]. - The total equity attributable to shareholders of the parent company rose to CNY 2,233,930,903.26, up from CNY 1,884,762,462.28, marking an increase of around 18.5%[24]. Shareholder Information - The company reported a total of 70,448 common shareholders at the end of the reporting period[6]. - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, held 24.86% of the shares, amounting to 118,997,902 shares[6]. Government Subsidies - The company received government subsidies amounting to CNY 4,910,172.94 during the reporting period[4]. - The company received government subsidies related to assets amounting to ¥23,931,592.60, a 175.34% increase[10]. Research and Development - Development expenses increased by 54.32% to ¥12,853,783.85, driven by higher capitalized R&D investments[10]. - R&D expenses grew by 47.27% to ¥39,955,815.11, reflecting increased investment in internet healthcare[10]. - The company is in the process of developing a continuous glucose monitoring system (CGMS) and expanding its diabetes care services[16]. - The company has initiated projects for smart factory upgrades and new product developments, including a new generation of smart thermometers and smart ultraviolet air disinfection machines[16]. Financial Stability and Strategy - The company is focused on maintaining its financial stability while exploring new strategies for market expansion and product development[45]. - The company has implemented a new leasing standard, which may affect future financial reporting[45]. - The company has not undergone an audit for the first quarter report, indicating that the figures are unaudited[45].